JBIO Aerovate Therapeutics, Inc.: Earnings per share for the last twelve months

Aerovate Therapeutics Inc (JBIO) profitability is based on the success of pulmonary hypertension drug trials and adherence to FDA timelines. On GURU.Markets, this linear chart showing a snapshot of the annual EPS TTM indicator demonstrates that the metric level is -2.38. The potential for global scaling via patents is currently offset by a loss of pricing power due to the failure of a key drug, which is forcing the company to undergo restructuring.
Analytical breakdowns and data insights for company Aerovate (JBIO)

Net income per share (TTM) reflects the actual annual return of a single security, stripping away market noise to assess the business's fundamental ability to generate capital. By analyzing the fundamental EPS TTM metric for Aerovate Therapeutics Inc (JBIO), an investor can see the impact of minimal operating expenses and strict laboratory environmental regulations on final margins, which is critical when forecasting the asset's value.